M.D., Professor of Medicine, Pharmacology, Pathology, Microbiology and Immunology, Vanderbilt University
At Vanderbilt University Medical Center Dr. Elizabeth Phillips lab studies the development of genetic, molecular and cellular signals to predict and prevent severe life-threatening adverse drug reactions using novel single cell technologies and mass cytometry. She is the John A. Oates Chair in Clinical Research and Director of Personalized Immunology in the Center for Drug Safety and Immunology. She is a physician scientist clinically trained in Infectious diseases and clinical pharmacology who has established new clinical and research programs in drug hypersensitivity, pharmacogenomics and personalized immunology across different healthcare systems. Amongst her greatest translational accomplishments between 2002-2008 she led the development of the HLA-B*57:01 genetic predictor for abacavir hypersensitivity from its discovery through implementation. Important work accomplished since the implementation of HLA-B*57:01 testing has been in elucidating the specific immunopathogenesis of abacavir hypersensitivity and other immunology-mediated drug hypersensitivity syndromes and new genetic discoveries such HLA-A*32:01 and vancomycin-induced drug reaction and eosinophilia and systemic symptoms.